{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T04:30:16Z","timestamp":1727065816944},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s00105-022-05078-2","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T10:04:06Z","timestamp":1668679446000},"page":"907-914","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tumormikromilieu des Melanoms\u00a0\u2013 Einfluss moderner Therapien"],"prefix":"10.1007","volume":"73","author":[{"given":"Judith","family":"Sirokay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelia","family":"Mauch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,17]]},"reference":[{"issue":"7490","key":"5078_CR1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nature13111","volume":"507","author":"T Bald","year":"2014","unstructured":"Bald\u00a0T et al (2014) Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma. Nature 507(7490):109\u2013113","journal-title":"Nature"},{"key":"5078_CR2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00343","author":"JA Chesney","year":"2022","unstructured":"Chesney JA, Ribas A et al (2022) Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma. J\u00a0Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.22.00343","journal-title":"Clin Oncol"},{"issue":"26","key":"5078_CR3","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1200\/JCO.21.00675","volume":"39","author":"A Diab","year":"2021","unstructured":"Diab\u00a0A, Tykodi\u00a0SS et al (2021) Bempegaldesleukin plus nivolumab in first-line metastatic melanoma. J\u00a0Clin Oncol 39(26):2914\u20132925","journal-title":"J Clin Oncol"},{"key":"5078_CR4","doi-asserted-by":"publisher","first-page":"102962","DOI":"10.1016\/j.ebiom.2020.102962","volume":"59","author":"A Fr\u00f6hlich","year":"2020","unstructured":"Fr\u00f6hlich\u00a0A, Sirokay\u00a0J et\u00a0al (2020) Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma. eBioMedicine 59:102962","journal-title":"eBioMedicine"},{"key":"5078_CR5","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1038\/s41467-019-12160-2","volume":"10","author":"J Griess","year":"2019","unstructured":"Griess\u00a0J et\u00a0al (2019) B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nat Commun 10:4186","journal-title":"Nat Commun"},{"key":"5078_CR6","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature22396","volume":"545","author":"SR Gordon","year":"2017","unstructured":"Gordon\u00a0SR, Maute\u00a0RL et al (2017) PD\u20111 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 545:495\u2013499","journal-title":"Nature"},{"issue":"3","key":"5078_CR7","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1158\/0008-5472.CAN-07-2491","volume":"68","author":"KS Hoek","year":"2008","unstructured":"Hoek\u00a0KS, Eichhoff\u00a0OM et\u00a0al (2008) In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res 68(3):650\u2013656","journal-title":"Cancer Res"},{"key":"5078_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.06.005","author":"A Indini","year":"2022","unstructured":"Indini A, Massi D et al (2022) Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges. Semin Cancer Biol. https:\/\/doi.org\/10.1016\/j.semcancer.2022.06.005","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"5078_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11845-016-1464-0","volume":"186","author":"A Korniluk","year":"2017","unstructured":"Korniluk\u00a0A, Koper\u00a0O et\u00a0al (2017) From inflammation to cancer. Ir J Med Sci 186(1):57\u201362","journal-title":"Ir J Med Sci"},{"key":"5078_CR10","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.3390\/cancers14071710","volume":"14","author":"M Kuske","year":"2022","unstructured":"Kuske\u00a0M, Haist\u00a0M et al (2022) Immunomodulatory properties of immune checkpoint inhibitors\u2014more than boosting T\u2011cell responses? Cancers 14:1710","journal-title":"Cancers"},{"issue":"4","key":"5078_CR11","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.cell.2016.11.037","volume":"168","author":"AW Lambert","year":"2017","unstructured":"Lambert\u00a0AW, Pattabiraman\u00a0DR, Weinberg\u00a0RA (2017) Emerging biological principles of metastasis. Cell 168(4):670\u2013691","journal-title":"Cell"},{"issue":"7420","key":"5078_CR12","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/nature11538","volume":"490","author":"J Landsberg","year":"2012","unstructured":"Landsberg\u00a0J, Kohlmeyer\u00a0J et al (2012) Melanomas resist T\u2011cell therapy through inflammation-induced reversible dedifferentiation. Nature 490(7420):412\u2013416","journal-title":"Nature"},{"key":"5078_CR13","doi-asserted-by":"publisher","first-page":"e002995","DOI":"10.1136\/jitc-2021-002995","volume":"9","author":"PKH Lau","year":"2021","unstructured":"Lau\u00a0PKH, Feran\u00a0B, Smith\u00a0L et al (2021) Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD\u20111 Resistance Signature (IPRES). J\u00a0Immunother Cancer 9:e2995","journal-title":"J Immunother Cancer"},{"issue":"1","key":"5078_CR14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ccell.2021.11.002","volume":"40","author":"H Li","year":"2022","unstructured":"Li\u00a0H, Xiao\u00a0Y et\u00a0al (2022) The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1. Cancer Cell 40(1):36\u201352.e9","journal-title":"Cancer Cell"},{"issue":"8","key":"5078_CR15","doi-asserted-by":"publisher","first-page":"P1083","DOI":"10.1016\/S1470-2045(19)30274-8","volume":"20","author":"G Long","year":"2019","unstructured":"Long\u00a0G, Dummer\u00a0R (2019) Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a\u00a0phase 3, randomised, double-blind study. Lancet Oncol 20(8):P1083\u2013P1097","journal-title":"Lancet Oncol"},{"key":"5078_CR16","doi-asserted-by":"publisher","first-page":"e002273","DOI":"10.1136\/jitc-2020-002273","volume":"9","author":"KT Lynch","year":"2021","unstructured":"Lynch\u00a0KT et al (2021) Heterogeneity in tertiary lymphoid structure B\u2011cells correlates with patient survival in metastatic melanoma. J\u00a0Immunother Cancer 9:e2273","journal-title":"J Immunother Cancer"},{"issue":"10","key":"5078_CR17","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1002\/ijc.33252","volume":"147","author":"M Mengoni","year":"2020","unstructured":"Mengoni\u00a0M et al (2020) The aryl hydrocarbon receptor promotes inflammation-induced dedifferentiation and systemic metastatic spread of melanoma cells. Int J Cancer 147(10):2902\u20132913","journal-title":"Int J Cancer"},{"key":"5078_CR18","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1172\/JCI21583","volume":"114","author":"Munn","year":"2004","unstructured":"Munn et al (2004) Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J\u00a0Clin Invest 114:280\u2013290","journal-title":"J Clin Invest"},{"issue":"22","key":"5078_CR19","doi-asserted-by":"publisher","first-page":"12276","DOI":"10.3390\/ijms222212276","volume":"22","author":"E Pach","year":"2021","unstructured":"Pach\u00a0E, K\u00fcmper\u00a0M et al (2021) Extracellular matrix remodeling by fibroblast-MMP14 regulates melanoma growth. Int J Mol Sci 22(22):12276","journal-title":"Int J Mol Sci"},{"key":"5078_CR20","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(00)49915-0","volume":"1","author":"S Paget","year":"1889","unstructured":"Paget\u00a0S (1889) The distribution of secondary growths in cancer of the breast. Lancet 1:571\u2013573","journal-title":"Lancet"},{"issue":"5","key":"5078_CR21","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nrc.2017.6","volume":"17","author":"H Peinado","year":"2017","unstructured":"Peinado\u00a0H, Zhang\u00a0H et al (2017) Pre-metastatic niches: organ-specific homes for metastases. Nat Rev Cancer 17(5):302\u2013317","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"5078_CR22","doi-asserted-by":"publisher","first-page":"3500","DOI":"10.1158\/0008-5472.CAN-06-4626","volume":"67","author":"GC Prendergast","year":"2007","unstructured":"Prendergast\u00a0GC, Jaffee\u00a0EM (2007) Cancer immunologists and cancer biologists: why we didn\u2019t talk then but need to now. Cancer Res 67(8):3500\u20133504","journal-title":"Cancer Res"},{"key":"5078_CR23","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.3390\/cancers12071823","volume":"12","author":"I Proietti","year":"2020","unstructured":"Proietti\u00a0I, Skroza\u00a0N et al (2020) BRAF inhibitors: molecular targeting and Immuno-modulatory actions. Cancers 12:1823","journal-title":"Cancers"},{"key":"5078_CR24","first-page":"6","volume":"20","author":"RJ Sullivan","year":"2022","unstructured":"Sullivan\u00a0RJ (2022) Role of triple therapy in melanoma. Clin Adv Hematol Oncol 20:6","journal-title":"Clin Adv Hematol Oncol"},{"key":"5078_CR25","doi-asserted-by":"publisher","first-page":"909580","DOI":"10.3389\/fimmu.2022.909580","volume":"13","author":"N Sun","year":"2022","unstructured":"Sun\u00a0N, Tian\u00a0Y et\u00a0al (2022) Metabolic rewiring directs melanoma immunology. Front Immunol 13:909580","journal-title":"Front Immunol"},{"issue":"9","key":"5078_CR26","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1158\/0008-5472.CAN-20-3510","volume":"81","author":"S Tartey","year":"2021","unstructured":"Tartey\u00a0S, Neale\u00a0G et al (2021) A MyD88\/IL1R axis regulates PD\u20111 expression on tumor-associated macrophages and sustains their immunosuppressive function in melanoma. Cancer Res 81(9):2358\u20132372","journal-title":"Cancer Res"},{"issue":"11","key":"5078_CR27","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/JCO.19.01598","volume":"38","author":"MH Taylor","year":"2020","unstructured":"Taylor\u00a0MH, Lee\u00a0CH et\u00a0al (2020) Phase IB\/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. J\u00a0Clin Oncol 38(11):1154\u20131163","journal-title":"J Clin Oncol"},{"key":"5078_CR28","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.immuni.2020.03.001","volume":"52","author":"A Teijeira","year":"2020","unstructured":"Teijeira\u00a0A et\u00a0al (2020) CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity. Immunity 52:856\u2013871","journal-title":"Immunity"},{"issue":"1","key":"5078_CR29","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi\u00a0HA, Schadendorf\u00a0D et al (2022) RELATIVITY-047 investigators. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N\u00a0Engl J Med 386(1):24\u201334","journal-title":"N Engl J Med"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-022-05078-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-022-05078-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-022-05078-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T11:05:34Z","timestamp":1669374334000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-022-05078-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,17]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["5078"],"URL":"https:\/\/doi.org\/10.1007\/s00105-022-05078-2","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,17]]},"assertion":[{"value":"11 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.\u00a0Sirokay hat Honorare f\u00fcr Vortr\u00e4ge, Beratert\u00e4tigkeiten und Reiseunterst\u00fctzung durch die Firmen Roche, MSD, BMS, Novartis und Pierre Fabre erhalten. Weiterhin bestand F\u00f6rderung von Forschungsprojekten durch die Deutsche Dermatologische Gesellschaft und den Galderma F\u00f6rderkreis e.\u00a0V. C.\u00a0Mauch hat Honorare und Reisekosten durch die Firmen Roche, MSD, BMS, Novartis und Pierre Fabre erhalten.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autorinnen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}